Considering the redox and hypoxia properties in tumor microenvironment, the lab designed an emerging nanomedicine using silver nanoparticle with chelating As(V) ions. This nanomedicine displayed the features of glutathione (GSH) stimulus responsive ability and endosomal escape. The GPx and SOD enzymes' activity can be specifically inhibited by nanomedicine in vivo, which triggered LC3-mediated autophagy. Results from both in vitro and in vivo experiments support the use of As-based chemotherapy, opening the path for effective boronate affinity-based arsenic chemotherapeutics enabled by nanomedicine for on-demand site-specific cancer combination treatment of GBM tumors. The research paper was published in ACS Applied Materials & Interfaces 2022, 14, 32, 36487–36502 (IF=10.383). Ph.D. candidate Jiliang Yan and Dr. Sumaira Hanif are the first authors, and Dr. Haigang Wu and Dr. Pir Muhammad are co-corresponding authors.

Paper link: https://doi.org/10.1021/acsami.2c12076